Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: voriconazole Clear all
Terminated Phase 1 Interventional

Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease

NCT01950507
View directory record Official record
Conditions
Stem Cell Transplantation, Graft vs Host Disease
Interventions
Budesonide, Fluconazole, Voriconazole, Micafungin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
13 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional

Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections

NCT00015665
View directory record Official record
Conditions
Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

NCT00353158
View directory record Official record
Conditions
Healthy Volunteers, Fungal Infections, Bacterial Infections
Interventions
Doxycycline, Voriconazole
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
8 Years to 100 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 24, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

NCT03327727
View directory record Official record
Conditions
Invasive Aspergillosis, Invasive Pulmonary Aspergillosis
Interventions
Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
Drug
Lead sponsor
Vical
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

NCT01503515
View directory record Official record
Conditions
Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis, Voriconazole
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Months to 20 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
46
States / cities
Phoenix, Arizona • Loma Linda, California • Oakland, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 24, 2026, 10:22 PM EDT
Terminated Phase 1 Interventional Results available

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

NCT05458102
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
Vesatolimod, Cobicistat, Voriconazole, Rifabutin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Long Beach, California • Miami, Florida • West Palm Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 24, 2026, 10:22 PM EDT
Withdrawn Phase 2 Interventional

Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis

NCT01207128
View directory record Official record
Conditions
Aspergillosis
Interventions
Voriconazole, micafungin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 24, 2026, 10:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

NCT04988555
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA), Intensive chemotherapy with 7 + 3
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Newport Beach, California • Palo Alto, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

NCT00833482
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1), HIV Infections
Interventions
Voriconazole, Atazanavir, Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 24, 2026, 10:22 PM EDT
Recruiting Phase 1 Interventional

Imetelstat Combinations in Relapsed AML

NCT07320235
View directory record Official record
Conditions
Relapsed Acute Myeloid Leukemia
Interventions
Imetelstat, Azacitidine, Venetoclax
Drug
Lead sponsor
Douglas Tremblay
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

NCT00066599
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Interventions
voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Orange, California • San Diego, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers

NCT02731638
View directory record Official record
Conditions
Corneal Ulcer, Fungal Keratitis
Interventions
Intrastromal voriconazole, Natamycin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 24, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Results available

A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

NCT00836875
View directory record Official record
Conditions
Invasive Aspergillosis
Interventions
Voriconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Oakland, California • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Sep 24, 2026, 10:22 PM EDT
Terminated Phase 4 Interventional Results available

Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

NCT00620074
View directory record Official record
Conditions
Aspergillosis
Interventions
voriconazole, anidulafungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Atlanta, Georgia • Detroit, Michigan • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants

NCT06493409
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Repotrectinib, Voriconazole, Quinidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 24, 2026, 10:22 PM EDT
Terminated Phase 1Phase 2 Interventional

An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend

NCT00150319
View directory record Official record
Conditions
Kidney Failure
Interventions
Vfend®; I.V.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
New Orleans, Louisiana • Minneapolis, Minnesota • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2008 · Synced Sep 24, 2026, 10:22 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections

NCT00059878
View directory record Official record
Conditions
Infection, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant interferon gamma, voriconazole
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Little Rock, Arkansas • Gainesville, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02014558
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Gilteritinib, Voriconazole, Midazolam, Cephalexin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 24, 2026, 10:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional

Voriconazole to Treat Fungal Infections

NCT00001940
View directory record Official record
Conditions
Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

NCT00531479
View directory record Official record
Conditions
Aspergillosis
Interventions
voriconazole, anidulafungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease

NCT00792246
View directory record Official record
Conditions
Graft Versus Host Disease, Stem Cell Transplantation
Interventions
voriconazole
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
Up to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)

NCT00075803
View directory record Official record
Conditions
Lymphoma, Infection, Leukemia
Interventions
Fluconazole, Voriconazole
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
33
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 24, 2026, 10:22 PM EDT